Item 8.01. Other Events.
On May 29, 2012 Dyax Corp. ("Dyax") and Sigma-Tau Rare Diseases S.A., as
successor-in-interest to Defiante Farmaceutica S.A. ("Sigma-Tau"), entered into
a Fourth Amendment (the "Fourth Amendment") to the Joint Development and License
Agreement dated effective as of June 18, 2010, as amended by the First Amendment
to Joint Development and License Agreement dated December 21, 2010, the Second
Amendment to Joint Development and License Agreement dated May 21, 2011 and the
Third Amendment to Joint Development and License Agreement dated December 26,
2011.
The Fourth Amendment eliminates Sigma-Tau's rights to develop and commercialize
KALBITOR (ecallantide) in Brazil, Argentina, the Middle East and North Africa,
and also removes Sigma-Tau's payment obligations to Dyax in relation to these
territories.
Add
DYAX to Portfolio
Set Alert
Email to a
Friend